The WHO Pandemic agreement, language on mutually agreed terms for technology transfer, and claims under investor-state dispute resolution (ISDS)

This is an annex to the document: KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024, which is available as a PDF here: KEI.MutuallyAgreedTerms.A_INB_9_3Rev1.22April2024draft Annex on Investor-State Dispute… Continue Reading

KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024

PDF version is available here: KEI.MutuallyAgreedTerms.A_INB_9_3Rev1.22April2024draft KEI comments on six references to “mutually agreed terms” in the WHO pandemic agreement negotiating text: A/INB/9/3 Rev.1, 22 April 2024 James Love Knowledge Ecology International April 28, 2024, revised April 29, 2024 Introduction… Continue Reading

Request for CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498 authorization and consent to use three patents listed in the FDA Orange Book for the cancer drug enzalutamide

Letter from KEI, UACT and UAEM to Chiquita White Brooks-Lasure, Administrator of the Office of the Administrator, Centers for Medicare and Medicaid Services, at HHS, asking that CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498… Continue Reading